# familial chylomicronemia syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/familial-chylomicronemia-syndrome

> 6 upcoming FDA catalysts in familial chylomicronemia syndrome: TRYNGOLZA (olezarsen, IONS) on June 2027 (primary completion); TRYNGOLZA (olezarsen, IONS) on Jun to Sep 2027 (topline data readout); TRYNGOLZA (olezarsen, IONS) on February 2028 (primary completion); TRYNGOLZA (olezarsen, IONS) on Feb to May 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 19, 2024 | [TRYNGOLZA (olezarsen) FDA approval](https://sec-api.dev/pdufa/olezarsen) | IONS | familial chylomicronemia syndrome | completed, approved | "On December 19, 2024, Ionis Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/874015/000114036124050057/ef20040455_8k.htm)) |
| May 12, 2025 | [REDEMPLO (plozasiran) NDA/BLA acceptance](https://sec-api.dev/pdufa/plozasiran) | ARWR | familial chylomicronemia syndrome | completed | "•Announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000162828025024675/arwr-202505128kex991.htm)) |
| June 2027 | [TRYNGOLZA (olezarsen) primary completion](https://sec-api.dev/pdufa/olezarsen) | IONS | Familial Chylomicronemia Syndrome | scheduled | "NCT05185843 (A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05185843)) |
| Jun to Sep 2027 | [TRYNGOLZA (olezarsen) topline data readout](https://sec-api.dev/pdufa/olezarsen) | IONS | Familial Chylomicronemia Syndrome | scheduled | "NCT05185843 (A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05185843)) |
| February 2028 | [TRYNGOLZA (olezarsen) primary completion](https://sec-api.dev/pdufa/olezarsen) | IONS | Familial Chylomicronemia Syndrome | scheduled | "NCT05130450 (A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05130450)) |
| Feb to May 2028 | [TRYNGOLZA (olezarsen) topline data readout](https://sec-api.dev/pdufa/olezarsen) | IONS | Familial Chylomicronemia Syndrome | scheduled | "NCT05130450 (A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05130450)) |
| August 2030 | [TRYNGOLZA (olezarsen) primary completion](https://sec-api.dev/pdufa/olezarsen) | IONS | Familial Chylomicronemia Syndrome | scheduled | "NCT07727538 (A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07727538)) |
| Aug to Nov 2030 | [TRYNGOLZA (olezarsen) topline data readout](https://sec-api.dev/pdufa/olezarsen) | IONS | Familial Chylomicronemia Syndrome | scheduled | "NCT07727538 (A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07727538)) |

## Drugs

- [TRYNGOLZA (olezarsen)](https://sec-api.dev/pdufa/olezarsen) (IONS)
- [REDEMPLO (plozasiran)](https://sec-api.dev/pdufa/plozasiran) (ARWR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/familial-chylomicronemia-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "familial chylomicronemia syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/familial-chylomicronemia-syndrome

```bibtex
@misc{secapidev_indications_familial_chylomicronemia_syndrome_20261116,
  title        = {familial chylomicronemia syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/familial-chylomicronemia-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_familial_chylomicronemia_syndrome_20261116","title":"familial chylomicronemia syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/familial-chylomicronemia-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
